FunPep Co., Ltd.

FunPep Co., Ltd. is a biotechnology company engaged in the research and development of pharmaceutical drugs, functional cosmetics, and medical devices in Japan and internationally. Its pipeline includes SR-0379, a functional peptide in Phase III clinical trials for skin ulcers; FPP003, an antibody-inducing peptide in Phase II trials for psoriasis and ankylosing spondylitis; FPP004X, an antibody-inducing peptide in Phase I trials for pollinosis; and FPP005, an antibody-inducing peptide in pre-clinical development for psoriasis. The company is also developing Curepeptin, an antimicrobial peptide that disrupts bacterial cell membranes. Incorporated in 2013, FunPep is headquartered in Ibaraki, Japan.